CONCORD HC GP2453.HKValuation Analysis

As of Oct 16, 2026, CONCORD HC GP (2453.HK) trades at a negative P/E (-3.13x, due to a recent net loss), P/B of 0.28x, P/S of 0.94x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 6th percentile over the trailing 10Y window (vs. 6th percentile over 3Y); P/S sits at the 3rd percentile over the trailing 10Y window (vs. 3rd percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 7th percentile within its industry and the 20th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/B percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. CONCORD HC GP operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.